58,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
29 °P sammeln
  • Broschiertes Buch

Strongyloidiasis is one of the important intestinal nematode diseases and it is estimated that worldwide between 50-200 million people are infected by the human pathogen Strongyloides stercoralis. For research purposes the closely related parasitic nematode S. ratti can be used to study stage development, life cycle and parasitism. The high genetic similarity then allows to draw parallels between the human parasite and other Strongylid nematodes. This work presents the establishment of the S. ratti life cycle at the BNI-Hamburg and the proteomic analysis of E/S and extract proteins from…mehr

Produktbeschreibung
Strongyloidiasis is one of the important intestinal nematode diseases and it is estimated that worldwide between 50-200 million people are infected by the human pathogen Strongyloides stercoralis. For research purposes the closely related parasitic nematode S. ratti can be used to study stage development, life cycle and parasitism. The high genetic similarity then allows to draw parallels between the human parasite and other Strongylid nematodes. This work presents the establishment of the S. ratti life cycle at the BNI-Hamburg and the proteomic analysis of E/S and extract proteins from various developmental stages at the Proteomics Center, Boston. Assuming that the protein patterns of larval and adult stages show differences, the results of the mass spectrometric analysis were compared. By choosing this approach it was possible to identify 1,081 proteins of S. ratti. Many of the proteins were also shown to be present as homologues in the culture supernatants and extracts of other parasitic nematodes and some proteins seem to be Strongyloides- specific.
Autorenporträt
Dr. Hanns Soblik studied Pharmaceutical Science and completed a post graduate course of molecular biology. After working at the Bernhard Nocht Institute for Tropical Medicine and a fellowship at the Proteomics Center (Children¿s Hospital, Boston, USA) he received his PhD in 2009 and started a career in the pharmaceutical industry.